New treatment options for fibromyalgia: critical appraisal of duloxetine
Nurcan Üçeyler1, Martin Offenbächer2, Frank Petzke3, Winfried Häuser4, Claudia Sommer11Department of Neurology, University of Würzburg, Germany; 2GRP – Generation Research Program, Human Science Center, University of Mu...
| Main Authors: | , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Dove Medical Press
2008-06-01
|
| Series: | Neuropsychiatric Disease and Treatment |
| Online Access: | http://www.dovepress.com/new-treatment-options-for-fibromyalgia-critical-appraisal-of-duloxetin-a1849 |
| _version_ | 1818405848121081856 |
|---|---|
| author | Nurcan Üçeyler Martin Offenbächer Frank Petzke Winfried Häuser Claudia Sommer |
| author_facet | Nurcan Üçeyler Martin Offenbächer Frank Petzke Winfried Häuser Claudia Sommer |
| author_sort | Nurcan Üçeyler |
| collection | DOAJ |
| description | Nurcan Üçeyler1, Martin Offenbächer2, Frank Petzke3, Winfried Häuser4, Claudia Sommer11Department of Neurology, University of Würzburg, Germany; 2GRP – Generation Research Program, Human Science Center, University of Munich, Germany; 3Department of Anesthesiology, University of Cologne, Germany; 4Center of Pain Therapy, Klinikum Saarbrücken gGmbH, Winterberg 1, Saarbrücken, GermanyAbstract: Fibromyalgia syndrome (FMS) is a chronic condition characterized by widespread pain, tender points, fatigue, and sleep disturbance. FMS leads to high disability levels, poor quality of life, and extensive use of medical care. Effective pharmacological treatment options are rare, and treatment effects are often of limited duration. Duloxetine is a new selective serotonin and norepinephrine reuptake inhibitor that is licensed for the treatment of pain in diabetic neuropathy. So far two randomized, placebo-controlled trials have investigated the short-term safety and efficacy of duloxetine 60 mg/day and 120 mg/day in patients suffering from FMS over a period of 12 weeks. Both dosages were superior to placebo in pain relief, and improvement in quality of life and depressive symptoms. The analgesic effect was largely independent of the antidepressant action of duloxetine. The higher dose of 120 mg/day further reduced the tender point count and elevated the tender point pain thresholds. Only mild to moderate adverse effects were reported. Duloxetine 60 mg/day and 120 mg/day has proven to be beneficial in the treatment of FMS symptoms. As true for other antidepressants further studies are needed to assess the long-term efficacy and safety of duloxetine as an additional pharmacological treatment option in FMS.Keywords: fibromyalgia syndrome, duloxetine, antidepressant, review, SNRI |
| first_indexed | 2024-12-14T09:02:34Z |
| format | Article |
| id | doaj.art-7e37398cd56049c5808e4f497c3f4657 |
| institution | Directory Open Access Journal |
| issn | 1176-6328 1178-2021 |
| language | English |
| last_indexed | 2024-12-14T09:02:34Z |
| publishDate | 2008-06-01 |
| publisher | Dove Medical Press |
| record_format | Article |
| series | Neuropsychiatric Disease and Treatment |
| spelling | doaj.art-7e37398cd56049c5808e4f497c3f46572022-12-21T23:08:47ZengDove Medical PressNeuropsychiatric Disease and Treatment1176-63281178-20212008-06-012008Issue 3525529New treatment options for fibromyalgia: critical appraisal of duloxetineNurcan ÜçeylerMartin OffenbächerFrank PetzkeWinfried HäuserClaudia SommerNurcan Üçeyler1, Martin Offenbächer2, Frank Petzke3, Winfried Häuser4, Claudia Sommer11Department of Neurology, University of Würzburg, Germany; 2GRP – Generation Research Program, Human Science Center, University of Munich, Germany; 3Department of Anesthesiology, University of Cologne, Germany; 4Center of Pain Therapy, Klinikum Saarbrücken gGmbH, Winterberg 1, Saarbrücken, GermanyAbstract: Fibromyalgia syndrome (FMS) is a chronic condition characterized by widespread pain, tender points, fatigue, and sleep disturbance. FMS leads to high disability levels, poor quality of life, and extensive use of medical care. Effective pharmacological treatment options are rare, and treatment effects are often of limited duration. Duloxetine is a new selective serotonin and norepinephrine reuptake inhibitor that is licensed for the treatment of pain in diabetic neuropathy. So far two randomized, placebo-controlled trials have investigated the short-term safety and efficacy of duloxetine 60 mg/day and 120 mg/day in patients suffering from FMS over a period of 12 weeks. Both dosages were superior to placebo in pain relief, and improvement in quality of life and depressive symptoms. The analgesic effect was largely independent of the antidepressant action of duloxetine. The higher dose of 120 mg/day further reduced the tender point count and elevated the tender point pain thresholds. Only mild to moderate adverse effects were reported. Duloxetine 60 mg/day and 120 mg/day has proven to be beneficial in the treatment of FMS symptoms. As true for other antidepressants further studies are needed to assess the long-term efficacy and safety of duloxetine as an additional pharmacological treatment option in FMS.Keywords: fibromyalgia syndrome, duloxetine, antidepressant, review, SNRIhttp://www.dovepress.com/new-treatment-options-for-fibromyalgia-critical-appraisal-of-duloxetin-a1849 |
| spellingShingle | Nurcan Üçeyler Martin Offenbächer Frank Petzke Winfried Häuser Claudia Sommer New treatment options for fibromyalgia: critical appraisal of duloxetine Neuropsychiatric Disease and Treatment |
| title | New treatment options for fibromyalgia: critical appraisal of duloxetine |
| title_full | New treatment options for fibromyalgia: critical appraisal of duloxetine |
| title_fullStr | New treatment options for fibromyalgia: critical appraisal of duloxetine |
| title_full_unstemmed | New treatment options for fibromyalgia: critical appraisal of duloxetine |
| title_short | New treatment options for fibromyalgia: critical appraisal of duloxetine |
| title_sort | new treatment options for fibromyalgia critical appraisal of duloxetine |
| url | http://www.dovepress.com/new-treatment-options-for-fibromyalgia-critical-appraisal-of-duloxetin-a1849 |
| work_keys_str_mv | AT nurcanampuumlampccedileyler newtreatmentoptionsforfibromyalgiacriticalappraisalofduloxetine AT martinoffenbampaumlcher newtreatmentoptionsforfibromyalgiacriticalappraisalofduloxetine AT frankpetzke newtreatmentoptionsforfibromyalgiacriticalappraisalofduloxetine AT winfriedhampaumluser newtreatmentoptionsforfibromyalgiacriticalappraisalofduloxetine AT claudiasommer newtreatmentoptionsforfibromyalgiacriticalappraisalofduloxetine |